Pint Pharma Breaks Ground With First Oral HAE Treatment Approval In Peru

We are thrilled to share that the General Directorate of Medicines Supplies and Drugs (DIGEMID) in Peru has approved ORLADEYO® (berotralstat) for daily oral use to prevent hereditary angioedema (HAE) attacks in both adults and children aged 12 and older. Hereditary angioedema, a genetic condition, triggers recurring episodes of abrupt, painful swelling in the skin, mucous membranes, and submucosal tissues. Until recently, treatment choices for HAE were sparse, leaving patients with compromised quality of life and a continual threat of severe attacks.

Dr. Valnei Canutti, Scientific Director of Pint Pharma, said “The approval of Orladeyo by DIGEMID is excellent news for the community of patients with hereditary angioedema in Peru. This innovative oral therapy represents a breakthrough for those living with this rare condition, offering an effective and convenient long-term prophylaxis option, preventing hereditary angioedema attacks.”

David Muñoz, CEO of Pint Pharma, further added “besides providing direct benefits to patients, the availability of Orladeyo in Peru highlights our continuous commitment to the advancement of research and innovation in the field of medical care for rare diseases.”

Mauricio Botero, General Manager of Pint Pharma in the LATAM North Cluster, said “The approval of Orladeyo is a great achievement for patients and proof of the successful collaboration among the medical community, regulators, and pharmaceutical companies in Peru to improve treatment options.”